Who
Albert Cha
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Frazier Life Sciences Acquisition Corp. II; Director, KalVista Pharmaceuticals; Director, Biohaven Pharmaceutical Holding Co; Director, Yarrow Bioscience; Director, Aclaris Therapeutics; Director, ProNAi Therapeutics; 10% owner, Capnia; Director, Biodel.
In numbers
- Trades disclosed
- 149
- Buys
- 15
- Sells
- 3
- Bought
- $57.0M
- Sold
- $2.2M
- Companies
- 9
- Companies where not an officer
- 8
- First trade
- 16 May 2007
- Last trade
- 15 Oct 2026
- Last filed
- 15 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 15 Oct 2026 | FLSC Frazier Life Sciences Acquisition Corp. IIFunds, Shells & SPACs | SEC FORM 4 Bought | $3.0M300,000 at $10.00 | filing |
| 26 Sep 2023filed 28 Sep 2023 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 11 Sep 2023filed 13 Sep 2023 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —6,000 at $0.00 | filing |
| 11 Sep 2023filed 13 Sep 2023 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 11 Sep 2023filed 13 Sep 2023 | KalVista Pharmaceuticals | SEC FORM 4 Code M | $40K6,000 at $6.71 | filing |
| 11 Sep 2023filed 13 Sep 2023 | KalVista Pharmaceuticals | SEC FORM 4 Code M | $95K12,000 at $7.88 | filing |
| 11 Sep 2023filed 13 Sep 2023 | KalVista Pharmaceuticals | SEC FORM 4 Sold | $189K18,000 at $10.50 | filing |
| 13 Oct 2022filed 17 Oct 2022 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 30 Sep 2021filed 1 Oct 2021 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 30 Oct 2020filed 3 Nov 2020 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $1.2M68,255 at $17.17 | filing |
| 30 Oct 2020filed 3 Nov 2020 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $822K47,431 at $17.34 | filing |
| 1 Oct 2020filed 2 Oct 2020 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 2 Oct 2019filed 3 Oct 2019 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 29 Jul 2019filed 30 Jul 2019 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $424K24,730 at $17.13 | filing |
| 29 Jul 2019filed 30 Jul 2019 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $88K5,137 at $17.13 | filing |
| 26 Jul 2019filed 30 Jul 2019 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $77K4,558 at $16.83 | filing |
| 26 Jul 2019filed 30 Jul 2019 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $369K21,942 at $16.83 | filing |
| 19 Jul 2019filed 19 Jul 2019 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $182K10,320 at $17.68 | filing |
| 19 Jul 2019filed 19 Jul 2019 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $886K49,680 at $17.84 | filing |
| 17 Jul 2019filed 19 Jul 2019 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $18K1,060 at $16.97 | filing |
News
Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) Stock: Insider Albert Cha Acquires 300,000 Sharesthemarketsdaily.com · 16 Oct 2026
1 headline in the last 90 days name Albert Cha; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.